Cargando…
Sipuleucel‐T associated inflammatory cardiomyopathy: a case report and observations from a large pharmacovigilance database
AIMS: The major cardiovascular (CV) adverse effects observed with sipuleucel‐T from large multi‐institutional clinical trials included thromboembolic events, myocardial infarction, and congestive heart failure in up to 0.3% of patients with CV risk factors. The incidence, outcomes, and mechanisms in...
Autores principales: | Moey, Melissa Y.Y., Jiwani, Rahim A., Takeda, Kotaro, Prenshaw, Karyn, Kreeger, R. Wayne, Inzerillo, John, Liles, Darla K., Marcu, C. Bogdan, Lebrun‐Vignes, Bénédicte, Morris, D. Lynn, Ardhanari, Sivakumar, Salem, Joe‐Elie |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8318408/ https://www.ncbi.nlm.nih.gov/pubmed/33938158 http://dx.doi.org/10.1002/ehf2.13400 |
Ejemplares similares
-
Graft Versus Host Disease Associated with Immune Checkpoint Inhibitors: A Pharmacovigilance Study and Systematic Literature Review
por: Nguyen, Lee S., et al.
Publicado: (2021) -
Drug-associated hyperammonaemia: a Bayesian analysis of the WHO Pharmacovigilance Database
por: Balcerac, Alexander, et al.
Publicado: (2022) -
Cardiotoxicity Associated with Gemcitabine: Literature Review and a Pharmacovigilance Study
por: Hilmi, Marc, et al.
Publicado: (2020) -
Neurologic toxicity associated with immune checkpoint inhibitors: a pharmacovigilance study
por: Johnson, Douglas B., et al.
Publicado: (2019) -
Concomitant use of renin-angiotensin-aldosterone system inhibitors prevent trastuzumab-induced cardiotoxicity in HER2+ breast cancer patients: an institutional retrospective study
por: Moey, Melissa Y. Y., et al.
Publicado: (2019)